News Search Results
Feb 24, 2026, 08:50 ET Draper and Partners Awarded ARPA-H Funding to Develop New In Silico Models of Human Physiology for Drug Development
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Feb 24, 2026, 08:30 ET Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership
technologiesSAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Therna Biosciences, a biotechnology company pioneering programmable RNA medicines, today announced the appointment of Devyn Smith, Ph.D., as an independent member of its Board of Directors,
More news about: Therna Biosciences
Feb 24, 2026, 08:05 ET Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
replay for 90 days after the call via the Rigel website.About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders
More news about: Rigel Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026
K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with high unmet medical need, today announced data from its Phase 1 clinical trial of KTX-2001
More news about: K36 Therapeutics
Feb 24, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Tax Certificate Transfer Program (NOL Program)The Technology Business Tax Certificate Transfer Program enables approved technology and biotechnology businesses with net operating losses to sell their unused net operating loss carryover (NOL) and unused research and development tax credits (R&D
More news about: Citius Pharmaceuticals, Inc.
Feb 24, 2026, 08:00 ET Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)
developing DNA methylation and other bead-based genomics assays in addition to NGS structural variant informatics. Illumina, Inc. is a leading American biotechnology company headquartered in San Diego, specializing in the development, manufacturing, and marketing of integrated systems for large-scale analysis
More news about: Klotho Neurosciences, Inc.
Feb 24, 2026, 07:30 ET Soligenix to Present at BIO Investment & Growth Summit
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Feb 24, 2026, 07:00 ET ERS Genomics launches new Early Access Express License
immune defence system, CRISPR/Cas9 is a precise, efficient tool for editing DNA in living organisms that has transformed research across genetics, biotechnology, and molecular biology.ERS Genomics offers non-exclusive licenses to the CVC Patents for research and commercial applications outside the
More news about: ERS Genomics
Feb 24, 2026, 07:00 ET Nanoscope Therapeutics Post-Hoc Clinical Analyses to be Presented at 2026 Macula Society Annual Meeting
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Feb 24, 2026, 03:42 ET ArisGlobal Launches XDI
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 24, 2026, 03:32 ET ArisGlobal Launches XDI
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 24, 2026, 02:50 ET BPC Instruments receives two repeat orders from Denmark within biogas applications
(publ)BPC Instruments is a Swedish technology company developing analytical instruments for renewable bioenergy and environmental biotechnology, including biogas and biodegradability testing. The systems enable advanced testing with higher accuracy and consistency, while reducing the time
More news about: BPC Instruments AB
Feb 23, 2026, 17:30 ET Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Feb 23, 2026, 17:00 ET Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
responsible for 60% and Vir Biotechnology responsible for 40% of all costs. Vir Biotechnology will continue the ongoing Phase 1 trial, until responsibility is transitioned to Astellas, after which Astellas will be responsible for all development activities. In the U.S., Vir Biotechnology will have the option
More news about: Astellas Pharma Inc.
Feb 23, 2026, 16:05 ET BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Conference ID: 4503000 About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 23, 2026, 16:00 ET New ACVIM Consensus Statement Highlights Visbiome Vet's De Simone Formulation in Diet-First Approach
https://academic.oup.com/jvim/article/40/1/aalaf017/8429723About ExeGi Pharma ExeGi Pharma LLC is a biotechnology company specializing in the development and commercialization of live biotherapeutic drugs for humans and probiotic agents for both humans and pets. With
More news about: ExeGi Pharma
Feb 23, 2026, 13:12 ET Rubin Rudman Partner David Wittmann Named a 2026 "Go To Business Transaction Lawyer" by Massachusetts Lawyers Weekly
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Feb 23, 2026, 12:53 ET PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions
Inc., a pioneering medical device startup developing advanced vascular access solutions for oncology, announced today that David Snow, a seasoned biotechnology and pharmaceutical executive, has joined its Board of Directors. Snow's appointment strengthens the company's leadership as it advances the development
More news about: PorTal Access, Inc.
Feb 23, 2026, 11:00 ET Stäubli Robotics Showcases New Sterimove at INTERPHEX 2026
RoboticsStäubli Robotics is a leading global provider of advanced industrial automation solutions. With decades of expertise across pharmaceuticals, biotechnology, medical device manufacturing, and high‑precision industrial sectors, Stäubli's robotic platforms are engineered for performance, reliability, and
More news about: Staubli Corporation
Feb 23, 2026, 10:30 ET Viral Vectors and Plasmid DNA Manufacturing Market to Reach $34.0 billion by 2033 at 20.4% CAGR: Allied Market Research
acquisitions enable companies to broaden their technology portfolios and enter adjacent markets quickly. Long-term strategic partnerships with biotechnology developers, academic research centers, and pharmaceutical firms provide steady demand and collaborative innovation opportunities. Partnerships can
More news about: Allied Market Research
Feb 23, 2026, 10:24 ET The HWP Group Announces Acquisition of Global Market Access Solutions
clients and patients alike."This acquisition further solidifies the position of HWP as a full‑service strategic partner to pharmaceutical and biotechnology companies navigating increasingly complex global markets, where clinical excellence must be matched by compelling economic evidence to achieve reimbursement,
More news about: Health & Wellness Partners
Feb 23, 2026, 10:01 ET Global Fluoropolymer Market to Reach US$16.7 Billion by 2033, Growing at 5.1% CAGR - Persistence Market Research
Nanofiltration), Application (Water & Wastewater Treatment, Desalination, Industrial Processing, Food & Beverage Processing, Pharmaceutical & Biotechnology, and Misc.), and Regional Analysis for 2026 – 2033
More news about: Persistence Market Research Pvt. Ltd.
Feb 23, 2026, 10:00 ET THE LOCKWOOD GROUP WELCOMES TOTAL HEALTH
continuum.About The Lockwood GroupThe Lockwood Group is a global health care services organization that partners with pharmaceutical, biotechnology, and health care companies to translate complex science into compelling, measurable strategies. With integrated capabilities spanning medical communications,
More news about: The Lockwood Group
Feb 23, 2026, 09:36 ET NASDAQ: QURE INVESTOR ALERT: Berger Montague Advises uniQure N.V. (NASDAQ: QURE) Investors of an April 13, 2026 Deadline
CLICK HERE.uniQure, headquartered in Amsterdam, the Netherlands, is a biotechnology company focused on the development of gene therapies for severe diseases, including Huntington's disease (HD).The Complaint alleges
More news about: Berger Montague
Feb 23, 2026, 09:00 ET Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company